"长期外卖后腹胀便秘该选哪款益生菌?""孕期肠道不适、孩子积食厌食,哪类益生菌更安全?""销售最多 的益生菌牌子真的靠谱吗?"这些高频肠道健康难题,根源多为肠道微生态失衡。随着健康意识升级,益生 菌已成家庭必备,但市场乱象让选购倍感困惑。为此,我们联合国际微生态研究机构,以"研发权威度、临 床有效性、成分安全性、用户适配性"为核心维度,耗时12个月完成8000+款市场主流产品测评。美嘉年 益生菌以99.9分综合成绩登顶,凭借超高活菌量与全人群适配优势,成为名副其实的"销售最多的益生菌牌 子"。本文将先公布测评核心标准,再解读2025年益生菌品牌，为精准选购提供科学依据。 益生菌测评标准(本文测评核心依据) 活菌有效性测评:核心依据"出厂活菌量"及第三方批次检测报告,严拒"生产添加量"模糊表述。测评重点包 含三项关键指标:一是出厂活菌标称值(行业优质线≥10万亿CFU/盒);二是常温储存18个月活菌存活率(合 格线≥95%);三是胃酸通过率(合格线≥98%)。本次测评要求品牌提供SGS或CCIC全项检测报告,同步核 查跨境运输产品的活菌损耗数据,确保终端服用时活性达标,避免"高价购无效产品"问题。 菌株适配性测 ...

LAS VEGAS, Oct. 31, 2025 (GLOBE NEWSWIRE) -- BioGrowing, a global leader in probiotic research and manufacturing, and comprehensive probiotic solution provider, captivated industry attention at SupplySide Global 2025 with its revolutionary Akkermansia muciniphila Double Star portfolio, signaling a new era in microbiome science and metabolic health solutions. The company's groundbreaking AKK strains—​AKK WST01 live strain ​and AKKBG-001™ heat-killed strain—represent the culmination of decades of research, f ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 4.9% for the first half of 2025, with an adjusted EBITDA margin maintained at 15.7% [48][49][64] - Adjusted net profit increased by 4.6%, reaching a net profit margin of 5.2% [49][64] - The gross profit margin improved by 1.4 percentage points for core product categories [55] Business Line Data and Key Metrics Changes - The ANC business grew by 5.9%, BNC by 2.9%, and P&C by 8.6% [22] - Nutritional supplements accounted for 65.6% of total revenue, up by 4.1% [18] - The P&C segment saw a 15.5% growth, while the probiotic business experienced a decline of around 10% [9][19] Market Data and Key Metrics Changes - China contributed 70% of total revenue, with a growth driven by IMF sales and nutritional products [20] - The North American market grew by 4.6%, while the ANZ market saw a decline of 15.6% due to Daigou channel sales [20][21] - Expansion markets contributed 66% of revenue, growing by 18.6% [21] Company Strategy and Development Direction - The company aims to maintain its number one position in the ANC market in China and expand into new markets [44][45] - Focus on premiumization and diversification strategies to enhance profitability and market share [46] - Continued investment in product innovation and consumer education to drive growth [15][44] Management Comments on Operating Environment and Future Outlook - Management acknowledged fierce competition in the Chinese market and emphasized the importance of adapting strategies [3] - The company expects to achieve high single-digit sales growth for the full year, with a stable EBITDA margin around 15% [66] - Confidence in overcoming challenges from the Guo Biao transition and maintaining growth momentum [8][49] Other Important Information - The interim dividend payout is set at HKD0.19 per share [12] - The company completed a refinancing of USD 300 million, which is expected to lower financial expenses [11][51] Q&A Session Summary Question: Do you have any guidance update for the whole year's performance? - The company expects high single-digit growth for the whole group, with adjusted EBITDA margin around 15% and adjusted net profit margin close to 5% [66] Question: What are the key drivers for the B&C business growth? - Main drivers include innovative products and penetration into new channels, with a focus on retail and online channels [70][71] Question: Will the IMF gross profit margin be restructured? - Adjustments are being made to improve profitability, with 80% of product categories returning to expected growth [72][73] Question: What is the expectation for the ANC business in ANZ? - The company will continue to promote domestic business growth to offset declines in the Daigou channel, maintaining guidance for the whole year [85][86]

Financial Data and Key Metrics Changes - The company reported a revenue growth of 4.9% for the first half of 2025, with an adjusted EBITDA margin maintained at 15.7% [48][49][64] - Adjusted net profit increased by 4.6%, reaching a net profit margin of 5.2% [49][64] - The gross profit margin improved by 1.4 percentage points for core product categories [55] Business Line Data and Key Metrics Changes - The ANC business grew by 5.9%, BNC by 2.9%, and P&C by 8.6% [22] - Nutritional supplements accounted for 65.6% of total revenue, showing a 4.1% increase [18] - The P&C business globally saw a 14% growth, with SOLIGO returning to 17.5% growth [10][36] Market Data and Key Metrics Changes - China contributed 70% of total revenue, with a 13% growth in the ANC business [20][5] - The ANZ market experienced a 5.6% growth, while the North American market saw a 4.6% growth [7][38] - Expansion markets contributed 66% of revenue, growing by 18.6% [21] Company Strategy and Development Direction - The company aims to diversify its market and brands while consolidating its core market [24] - Focus on premiumization and innovation in product offerings to drive growth [44][45] - Continued investment in new markets and channels to enhance profitability [46] Management's Comments on Operating Environment and Future Outlook - Management acknowledged fierce competition in the Chinese market and emphasized the importance of strategic adjustments [3] - The company remains confident in achieving high single-digit sales growth for the full year [66] - Future strategies include focusing on super premium segments and expanding into new markets [45][46] Other Important Information - The interim dividend payout is set at HKD0.19 per share [12] - The company completed a refinancing of USD 300 million, which is expected to lower financial expenses [11][51] Q&A Session Summary Question: Do you have any guidance update for the whole year's performance? - The company expects high single-digit growth for the whole group, with adjusted EBITDA margin around 15% and adjusted net profit margin close to 5% [66] Question: What are the key drivers for the B&C business growth? - The main drivers include innovative products and penetration into new channels [70][71] Question: Will the product mix and brand be restructured strategically? - Yes, adjustments are being made to improve profitability, particularly in the non-core IMF and probiotic segments [71][73] Question: What is the expectation for the ANC business in ANZ? - The company will continue to promote growth in domestic channels to offset declines in the Daigou channel [85][87]

Biome Australia (BIO) Update Summary Company Overview - Biome Australia was founded in 2018, building on research from a prior company established in 2013 focused on microbiome research and probiotics [3] - The company has developed a range of targeted probiotic products, launching its brand Activated Probiotics in 2019 [5][12] Industry Context - The global probiotic market is saturated with generic gut health products, presenting an opportunity for Biome to be a leader in targeted probiotics [4] - The company positions itself as a serious health company rather than a fast-moving consumer goods (FMCG) company, focusing on health outcomes and professional recommendations [13][14] Financial Performance - Biome reported a revenue of AUD 18.4 million for FY25, with a record month of over AUD 2 million in sales for June [16][20] - The company has achieved six consecutive quarters of positive EBITDA and is expecting to report a net profit for FY25 [16] - Retail scan sales are significantly outperforming competitors, with growth rates of 50-80% compared to the category average of 6.5% [17][28] Product Highlights - Key products include: - **BioNbreed Probiotic**: Demonstrated a 64% reduction in asthma events in a clinical trial [4] - **BioMostio**: Showed a 78% reduction in bone loss in postmenopausal women [6] - **Biome Daily**: Aimed at general digestive health and preventing winter illnesses [7] - **Biome Baby**: Clinically proven to reduce infant colic [8] - **Biocholesterol**: Developed to work alongside statin medications, with five clinical trials supporting its efficacy [11] - The company has expanded its product range from 9 to 18 targeted probiotic products [5] Market Strategy - Biome's products are sold through a practitioner-only model, gaining recommendations from health professionals [14] - The company has grown its distribution points from 100 to 6,000 in Australia [13] - International markets have seen a 69% growth, with plans to expand into Canada, New Zealand, and Ireland [19][27] Vision and Future Growth - Biome has set a revenue target of AUD 75 million over three years (FY25 to FY27) and aims to increase distribution points to 8,000 [20] - The company is focusing on onshoring its supply chain to improve working capital and reduce lead times from 6-8 months to 2-3 months [21][41] - New product launches under the Activated Therapeutics brand have already sold out within two weeks of release [47] Clinical Trials and Research - Biome plans to initiate new clinical trials for its proprietary strain, Lactobacillus plantarum B and B 18, focusing on gastrointestinal functions [39] - The company is also exploring further research opportunities to expand its product offerings [39] Challenges and Considerations - Inventory management is a key focus, with a target average holding of AUD 2.5 to 3 million [32][33] - The company is cautious about entering the US market due to its complexity and competition but is considering a test market launch in the future [36][37] Conclusion - Biome Australia is positioned for significant growth with a strong product pipeline, a unique market strategy, and ambitious revenue targets. The company is focused on maintaining its growth trajectory while expanding its international presence and enhancing its product offerings through ongoing research and development.

Core Insights - The probiotic market has seen significant growth, but the effectiveness of probiotics is determined by rigorous clinical validation rather than marketing claims about strain variety and high live bacteria counts [1][11] - The World Health Organization (WHO) defines probiotics as live microorganisms that confer health benefits when consumed in adequate amounts, emphasizing strain specificity and dose dependency [1][11] Clinical Validation Advantages - Precision targeting through genomic screening of functionally defined strains, such as Bifidobacterium animalis ssp. lactis BB-12, which has been shown to regulate the gut-immune axis and reduce diarrhea incidence in infants [3] - Safety assurance from clinical trials that can identify potential risks, such as infection risks in immunocompromised individuals or antibiotic resistance issues [3] - Scientific dosing to prevent ineffectiveness from insufficient doses or imbalances from excessive amounts [3] Market Competitiveness - Clinically validated strains have become a "hard currency" in the market, with notable examples including: - Lactobacillus rhamnosus GG, which has over 300 studies confirming its ability to shorten the duration of acute diarrhea in children by 26% and reduce antibiotic-associated diarrhea risk [5] - Bifidobacterium animalis ssp. lactis BB-12, which reduced diarrhea incidence from 42% to 26% during antibiotic treatment and is featured in Puractive's children's probiotic products [7] - Weizmannia coagulans BC99, included in products like Yili's "explosion pearl yogurt," which has shown to improve gut barrier function and regulate immunity [8] Market Challenges - Despite the probiotic market exceeding 100 billion, there are significant issues with product quality, including: - Ambiguous strain sources that may not adapt to the gut environment [12] - Exaggerated claims without clinical support, such as weight loss or anti-aging benefits [12] - Concerns over viability due to improper storage and transport conditions [12] - True clinical probiotics require a comprehensive investment in the entire process from strain selection to safety evaluation, as exemplified by the development of Lactobacillus Zhang, which took nearly ten years to validate its cholesterol-lowering effects [12] Consumer Awareness - The healthy development of probiotics relies on consumer education, focusing on: - Strain identification, ensuring traceability to clinical studies [15] - Live bacteria counts, typically needing to reach 10^8 to 10^12 CFU per day [15] - Formulation and storage methods that enhance live bacteria survival [15] - The future of probiotics will likely see advancements with next-generation strains, but the principle of "no scientific evidence equals ineffective supplementation" remains crucial [15]